What we do Panacea Biotec Ltd is a leading Indian research-driven health company specializing in vaccines and innovative pharmaceuticals across therapeutic areas including diabetes and oncology. |
Founded in 1,984 |
Market share Second largest vaccine producer in India with strong domestic and global presence in vaccines and formulations. |
Problem solved Develops vaccines and pharmaceuticals to combat infectious diseases, chronic conditions like diabetes, and cancer, addressing critical health needs. |
Top clients or who we serve Serves healthcare providers, governments, UN agencies, and patients globally; operates in B2B and B2C markets. |
Key management - |
Our journey and innovations Pioneered indigenously developed vaccines and oncology drugs; collaborations with global institutes; launched world’s first fully liquid tetravalent vaccine. |
Where we operate India, Germany, United States, and other overseas markets with expanding global footprint. |
Top products or what we offer Vaccines including EasySix™, Easyfour-TT™, pharmaceutical formulations for diabetes, oncology, pain management, and baby care products. |
Top brands EasySix™ (hexavalent vaccine), Easyfour-TT™ (tetravalent vaccine), Tacpan® (generic Tacrolimus brand), ChilRun® (pediatric nutrition). |
Raw materials needed Bulk drug substances, biological agents for vaccine production, active pharmaceutical ingredients sourced globally. |
Raw materials supplier Mix of domestic and international suppliers including biotechnology firms and chemical manufacturers. |
Recurring vs cyclical contribution Majority revenue is recurring from vaccine and pharmaceutical sales, supplemented by cyclical product launches and government contracts. |
Our industry position India’s second largest vaccine producer; strong research-driven pharmaceutical formulation business with growing global presence. |
Financial highlights FY25 consolidated revenue approx. ₹5590 million; net loss ₹87 million; impacted by lower vaccine sales but supported by grant and incentive income. |
Geographical revenue split ~28% domestic revenue, ~72% from overseas markets primarily Europe and Americas. |
Order book Received UNICEF supply orders worth over ₹171 crore for 2025 deliveries. |
Whats driving growth New vaccine launches, clinical trials of dengue vaccine, government incentives, and strategic global partnerships. |
Our future plans Scaling hexavalent vaccine production with $20M funding, launching dengue vaccine post-trial, expanding baby care portfolio. |
Our green promise Committed to sustainability with proposed renewable energy integration and eco-friendly production processes. |
Our people and values Dedicated workforce focused on innovation, compliance, and ethical healthcare delivery. |
Key challenges ahead Managing losses due to sales decline, regulatory approvals, and competitive vaccine market pressures. |
Interesting facts First to launch fully liquid wP-IPV based hexavalent vaccine in India; Phase III dengue vaccine trials underway. |
Risks and strategy Mitigating revenue dips by diversifying product lines, securing large government contracts, and enhancing R&D pipeline. |
